Hisatomo Ikehara

Hisatomo Ikehara

Auto-generated profile, based on publicly available information

Hisatomo Ikehara

Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in Digestion
Verified
Journal Article
Open access
PDF file
SSSho Suzuki
Sho Suzuki
CKChika Kusano
Chika Kusano
THToshiki Horii
Toshiki Horii
RIRyoji Ichijima
Ryoji Ichijima
HIHisatomo Ikehara
Hisatomo Ikehara
Background: Helicobacter pylori eradication treatments are widely performed to improve gastric mucosal inflammation, promote ulcer healing, and reduce the incidence of gastric cancer. However, there are several issues associated with H. pylori eradication treatment. First, various treatment regimens are currently used worldwide, and the standard treatment varies with region and country. Second, the antimicrobial resistance of H. pylori is increasing due to indiscriminate antibiotic use. Finally, gut microbiota dysbiosis is potentially induced by H. pylori treatment. Summary: Based on current international guidelines and a network meta-analysis comparing the effects of various treatment regimens, nonbismuth quadruple therapies for 10–14 days and vonoprazan-based triple therapy for 7 days are the currently recommended H. pylori treatment regimens. These regimens show good eradication rates of approximately 90%, even in areas where antimicrobial-resistant strains are highly prevalent. However, these regimens still have inherent drawbacks that may promote further increases in antimicrobial resistance and induce gut microbiota dysbiosis because of the empiric use of multiple antibiotics. Key Message: The ideal concept for the present and future H. pylori eradication treatment involves “a simple, cost-effective strategy that fosters compliance without having a negative impact on the gut microbiota or contributing to future antimicrobial resistance.” One interesting possibility that may fulfill this concept is a dual therapy involving vonoprazan and amoxicillin. This is the simplest treatment regimen that provides acceptable eradication rates, improves safety and tolerability, and minimizes the potential for increasing antimicrobial resistance or causing gut microbiota dysbiosis.

3 October 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
RIRyoji Ichijima
Ryoji Ichijima
HIHisatomo Ikehara
Hisatomo Ikehara
YSYorinobu Sumida
Yorinobu Sumida
TITaisuke Inada
Taisuke Inada
DNDaiki Nemoto
Daiki Nemoto
TGTakuji Gotoda
Takuji Gotoda

15 July 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
RIRyoji Ichijima
Ryoji Ichijima
HIHisatomo Ikehara
Hisatomo Ikehara
TMTakeshi Maeda
Takeshi Maeda
TSTomomi Sugita
Tomomi Sugita
THToshiki Horii
Toshiki Horii
TGTakuji Gotoda
Takuji Gotoda

25 February 2024 in Digestive Endoscopy
Verified
Journal Article
Closed access
RIRyoji Ichijima
Ryoji Ichijima
HIHisatomo Ikehara
Hisatomo Ikehara
DYDaisuke Yamaguchi
Daisuke Yamaguchi
YNYasuhiko Nagata
Yasuhiko Nagata
KOKanako Ogura
Kanako Ogura
TGTakuji Gotoda
Takuji Gotoda

23 July 2024 in DEN Open
Verified
Journal Article
Open access
KOKanako Ogura
Kanako Ogura
RIRyoji Ichijima
Ryoji Ichijima
HIHisatomo Ikehara
Hisatomo Ikehara
TSTomomi Sugita
Tomomi Sugita
DYDaisuke Yamaguchi
Daisuke Yamaguchi
YKYuichi Kanmura
Yuichi Kanmura
Objectives: To compare the efficacy and safety of sedation with midazolam and remimazolam for colorectal endoscopy.Methods: This single‐center, two‐arm, post‐hoc analysis of the REM‐IICTJP01 study investigated the efficacy and safety of remimazolam for gastrointestinal endoscopic sedation. We enrolled 40 and 208 patients who underwent colonoscopy under remimazolam and midazolam sedation, respectively, during the same period. The primary outcome was the time from the end of the colonoscopy until discharge. The secondary outcomes included the time from the end of the colonoscopy until awakening, dosage, and adverse events. Propensity score matching was employed to eliminate the effect of confounding factors.Results: Thirty‐seven patients in each group were matched. After propensity matching, the time to awakening after colonoscopy was 28.0 (13.0–37.0) min in the midazolam group and 0 (0–0) min in the remimazolam group; moreover, the time till discharge was 40.0 (35.0–46.5) min in the midazolam group and 0 (0–5.0) min in the remimazolam group, both of which were significantly shorter in the remimazolam group (p < 0.01). The number of additional doses was 0 (0–0) and 2 (1–3) in the midazolam and remimazolam groups, respectively. The total dose was 2.0 (2.0–3.5) and 6.0 (5.0–7.0) mg in the midazolam and remimazolam groups, respectively.Conclusions: Remimazolam yielded significantly faster times to awakening and discharge safely compared to midazolam.

3 April 2025 in Digestive Endoscopy
Verified
Journal Article
Closed access
HIHisatomo Ikehara
Hisatomo Ikehara
RIRyoji Ichijima
Ryoji Ichijima
YTYoji Takeuchi
Yoji Takeuchi
JKJun Kanazawa
Jun Kanazawa
TWTakuya Wada
Takuya Wada
HOHiroyuki Ono
Hiroyuki Ono